These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
200 related articles for article (PubMed ID: 18292291)
21. CD4+CD25+ regulatory T-cell deficiency in patients with hepatitis C-mixed cryoglobulinemia vasculitis. Boyer O; Saadoun D; Abriol J; Dodille M; Piette JC; Cacoub P; Klatzmann D Blood; 2004 May; 103(9):3428-30. PubMed ID: 14684420 [TBL] [Abstract][Full Text] [Related]
22. Improvement in psoriasis during rituximab therapy for mixed cryoglobulinemia type II. Moberg P; Charles JF; Respicio G; Venna SS; Rooney T Cutis; 2010 Sep; 86(3):133-5. PubMed ID: 21049729 [TBL] [Abstract][Full Text] [Related]
23. Efficacy and risk of rituximab in type II mixed cryoglobulinemia: a significant case report. Massari M; Catania A; Magnani G Dig Liver Dis; 2007 Sep; 39 Suppl 1():S134-5. PubMed ID: 17936216 [No Abstract] [Full Text] [Related]
24. B-cell depletion in the treatment of mixed cryoglobulinemia. Sansonno D; Tucci FA; Montrone M; Troiani L; Sansonno L; Gatti P; Lauletta G Dig Liver Dis; 2007 Sep; 39 Suppl 1():S116-21. PubMed ID: 17936212 [TBL] [Abstract][Full Text] [Related]
26. Rituximab in cryoglobulinaemic vasculitis, evidence for its effectivity: a case report and review of literature. Wink F; Houtman PM; Jansen TL Clin Rheumatol; 2011 Feb; 30(2):293-300. PubMed ID: 21053035 [TBL] [Abstract][Full Text] [Related]
27. Treatment with rituximab in patients with mixed cryoglobulinemia syndrome: results of multicenter cohort study and review of the literature. Ferri C; Cacoub P; Mazzaro C; Roccatello D; Scaini P; Sebastiani M; Tavoni A; Zignego AL; De Vita S Autoimmun Rev; 2011 Nov; 11(1):48-55. PubMed ID: 21821153 [TBL] [Abstract][Full Text] [Related]
28. Serum concentrations of interleukin 1beta, CXCL10, and interferon-gamma in mixed cryoglobulinemia associated with hepatitis C infection. Antonelli A; Ferri C; Ferrari SM; Ghiri E; Marchi S; Sebastiani M; Fallahi P J Rheumatol; 2010 Jan; 37(1):91-7. PubMed ID: 19918044 [TBL] [Abstract][Full Text] [Related]
29. The use of monoclonal antibody (rituximab) in the treatment of type II mixed cryoglobulinemia. Rego TC; Massumoto CM; Batista RS; Moura LH; Soares LM; Gomes AP Braz J Infect Dis; 2007 Feb; 11(1):174-5. PubMed ID: 17625752 [TBL] [Abstract][Full Text] [Related]
30. Assessment of free light chains in HCV-positive patients with mixed cryoglobulinaemia vasculitis undergoing rituximab treatment. Basile U; Gragnani L; Piluso A; Gulli F; Urraro T; Dell'Abate MT; Torti E; Stasi C; Monti M; Rapaccini GL; Zignego AL Liver Int; 2015 Sep; 35(9):2100-7. PubMed ID: 25800731 [TBL] [Abstract][Full Text] [Related]
31. Predominance of type 1 (Th1) cytokine production in the liver of patients with HCV-associated mixed cryoglobulinemia vasculitis. Saadoun D; Boyer O; Trébeden-Nègre H; Limal N; Bon-Durand V; Andreu M; Klatzmann D; Piette JC; Cacoub P J Hepatol; 2004 Dec; 41(6):1031-7. PubMed ID: 15582138 [TBL] [Abstract][Full Text] [Related]
32. PEGylated interferon alfa-2b and ribavirin treatment in patients with hepatitis C virus-related systemic vasculitis. Cacoub P; Saadoun D; Limal N; Sene D; Lidove O; Piette JC Arthritis Rheum; 2005 Mar; 52(3):911-5. PubMed ID: 15751068 [TBL] [Abstract][Full Text] [Related]
33. Efficacy and safety of rituximab in type II mixed cryoglobulinemia. Zaja F; De Vita S; Mazzaro C; Sacco S; Damiani D; De Marchi G; Michelutti A; Baccarani M; Fanin R; Ferraccioli G Blood; 2003 May; 101(10):3827-34. PubMed ID: 12560225 [TBL] [Abstract][Full Text] [Related]
34. The challenge of treating hepatitis C virus-associated cryoglobulinemic vasculitis in the era of anti-CD20 monoclonal antibodies and direct antiviral agents. Roccatello D; Sciascia S; Rossi D; Solfietti L; Fenoglio R; Menegatti E; Baldovino S Oncotarget; 2017 Jun; 8(25):41764-41777. PubMed ID: 28454112 [TBL] [Abstract][Full Text] [Related]
35. Infections in vasculitis. Guillevin L Best Pract Res Clin Rheumatol; 2013 Feb; 27(1):19-31. PubMed ID: 23507054 [TBL] [Abstract][Full Text] [Related]
36. Should rituximab be the rescue therapy for refractory mixed cryoglobulinemia associated with hepatitis C? Ahmed MS; Wong CF J Nephrol; 2007; 20(3):350-6. PubMed ID: 17557269 [TBL] [Abstract][Full Text] [Related]
37. Abnormal CD4 + T helper (Th) 1 cells and activated memory B cells are associated with type III asymptomatic mixed cryoglobulinemia in HCV infection. Kong F; Zhang W; Feng B; Zhang H; Rao H; Wang J; Cong X; Wei L Virol J; 2015 Jul; 12():100. PubMed ID: 26129991 [TBL] [Abstract][Full Text] [Related]
38. [Current possibilities for treatment for hepatitis C virus-induced cryoglobulinemic vasculitis and B-cell lymphoma]. Ignatova TM; Mukhin NA Ter Arkh; 2012; 84(11):81-8. PubMed ID: 23252255 [TBL] [Abstract][Full Text] [Related]
39. Pegylated interferon-alpha, ribavirin, and rituximab combined therapy of hepatitis C virus-related mixed cryoglobulinemia: a long-term study. Dammacco F; Tucci FA; Lauletta G; Gatti P; De Re V; Conteduca V; Sansonno S; Russi S; Mariggiò MA; Chironna M; Sansonno D Blood; 2010 Jul; 116(3):343-53. PubMed ID: 20308602 [TBL] [Abstract][Full Text] [Related]
40. Efficacy of tocilizumab in rituximab-refractory cryoglobulinemia vasculitis. Cohen C; Mekinian A; Saidenberg-Kermanac'h N; Stirnemann J; Fenaux P; Gherardi R; Fain O Ann Rheum Dis; 2012 Apr; 71(4):628-9. PubMed ID: 22121135 [No Abstract] [Full Text] [Related] [Previous] [Next] [New Search]